24
Participants
Start Date
September 14, 2017
Primary Completion Date
August 31, 2019
Study Completion Date
June 5, 2020
HIF-2alpha Inhibitor PT2385
Given PO
Pharmacological Study
Correlative studies
Laboratory Biomarker Analysis
Correlative studies
Pharmacogenomic Study
Correlative studies
Memorial Sloan-Kettering Cancer Center, New York
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh
Abrams Cancer Center of the University of Pennsylvania, Philadelphia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Wake Forest University Comprehensive Cancer Center, Winston-Salem
Cleveland Clinic Taussig Cancer Center, Cleveland
Henry Ford Hospital, Detroit
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles
UAB Comprehensive Cancer Center, Birmingham
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston
National Cancer Institute (NCI)
NIH
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
INDUSTRY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER